Our company was established in 2015 to provide a platform for predicting the efficacy and toxicity of drugs based on original three-dimensional cell cultures.
3D cell chip with hydrogel-based pillar structure is a technology that can overcome the problems of conventional two-dimensional cell culture and has been proven by the domestic and foreign pharmaceutical companies, hospitals and research institutes for superior technology.
In addition, we are establishing a base for providing optimal anti-cancer drugs using patient-derived cancer cells for the successful personalized medicine for cancer treatment.
It will give hope to the patients, reduce the economic cost to the family, and secure the market competitiveness by shortening the development time for the company that develops new drugs.
Therefore, MBD will grow into a global comprehensive biotechnology company based on steady research and development and honest business ethics.
Mission and Vision
Global No.1 comprehensive biotechnology company of patient personalized treatment
MBD Co., Ltd. is committed to providing customer satisfaction with a new paradigm for drug development and personalized cancer treatment
• A three-dimensional cell-based, high accuracy, easy-to-use, cost-effective provides total efficacy and toxicity assessment solution
• Automated analytical equipment and consumables manufacture and sale to Medical & Bio labs for pharmaceutical companies, hospitals, universities and research institutes
• New opportunities for rapid and inexpensive assessment of drug efficacy at very early phases of clinical study for individual cancer patients
+ Scientific Advisories
+ Professor, Pharmaceutics, Seoul National University (SNU)
+ Head, Medicinal Bioconvergence Research Center (BIOCON)
+ Senior Scientist, Cubist Pharmaceuticals, USA
+ Visiting proferssor, Scripps Research Institute, USA
+ Advisors to National Drug Screening Center, China
+ Postdoctoral fellow, MIT, USA
+ PhD, Brown University, USA
+ Head of High Content Screening and Technology Development, Ksilink, France
+ Principal Scientist, Institute for Refractory Cancer Research, Samsung Medical Center
+ Research professor in Sungkyunkwan University School of Medicine, Samsung Medical Center
+ Head of Discovery Biology Group & Screening Platform Technology Group, Institut Pasteur Korea
+ PhD, in Functional Genomics, Yonsei University
+ Professor, Department of Chemical & Biological Engineering, Cleveland State University, Cleveland, OH, USA
+ Co-founder and CTO, 3D MicroArray Inc, USA
+ Adjunct Faculty, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
+ Lead/Senior Scientist, Solidus Bioscience, Inc., San Francisco, CA, USA
+ Postdoctoral fellow, Rensselaer Polytechnic Institute (RPI), NY, USA
+ PhD, Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST)